Profile data is unavailable for this security.
About the company
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.
- Revenue in USD (TTM)14.24bn
- Net income in USD1.57bn
- Incorporated1979
- Employees48.00k
- LocationBoston Scientific Corp300 Boston Scientific WayMARLBOROUGH 01752-1291United StatesUSA
- Phone+1 (508) 683-4000
- Fax+1 (508) 650-8923
- Websitehttps://www.bostonscientific.com/en-US/Home.html
Mergers & acquisitions
Acquired company | BSX:NYQ since announced | Transaction value |
---|---|---|
Axonics Inc | 17.76% | 3.67bn |
Relievant Medsystems Inc | 29.23% | 850.00m |
Shockwave Medical Inc | 30.16% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DexCom Inc | 3.62bn | 541.50m | 53.77bn | 9.60k | 108.80 | 25.99 | 73.91 | 14.84 | 1.28 | 1.28 | 8.55 | 5.37 | 0.6215 | 3.04 | 4.29 | 377,322.90 | 9.29 | 8.30 | 13.11 | 10.50 | 63.65 | 65.90 | 14.95 | 14.14 | 2.48 | -- | 0.5465 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
Edwards Lifesciences Corp | 6.00bn | 1.40bn | 57.21bn | 19.80k | 41.34 | 8.60 | 37.05 | 9.53 | 2.30 | 2.30 | 9.85 | 11.06 | 0.6802 | 1.35 | 8.47 | 303,272.70 | 15.85 | 16.63 | 18.21 | 19.12 | 77.02 | 76.71 | 23.30 | 24.84 | 2.40 | -- | 0.0816 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
Becton Dickinson and Co | 19.49bn | 1.27bn | 71.22bn | 73.00k | 56.26 | 2.81 | 20.08 | 3.65 | 4.38 | 4.23 | 67.25 | 87.68 | 0.3699 | 3.31 | 8.57 | 267,013.70 | 2.47 | 2.37 | 2.89 | 2.70 | 41.37 | 45.78 | 6.68 | 6.95 | 0.6435 | 6.45 | 0.3887 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
Boston Scientific Corporation | 14.24bn | 1.57bn | 100.86bn | 48.00k | 64.07 | 5.22 | 36.47 | 7.08 | 1.07 | 1.07 | 9.73 | 13.16 | 0.4213 | 1.99 | 6.78 | 296,666.70 | 4.71 | 2.50 | 5.43 | 2.91 | 69.65 | 68.84 | 11.18 | 6.47 | 0.8170 | 5.16 | 0.3179 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
Medtronic PLC | 32.32bn | 4.20bn | 115.41bn | 95.00k | 27.56 | 2.23 | 16.71 | 3.57 | 3.15 | 3.15 | 24.27 | 38.95 | 0.3495 | 2.00 | 5.45 | 340,210.50 | 4.58 | 4.78 | 5.28 | 5.37 | 65.73 | 67.68 | 13.10 | 14.28 | 1.71 | 30.78 | 0.3263 | 72.49 | -1.45 | 0.8366 | -25.42 | -6.95 | 6.44 | 8.13 |
Stryker Corp | 20.50bn | 3.17bn | 136.40bn | 52.00k | 43.49 | 7.33 | 32.53 | 6.65 | 8.25 | 8.25 | 53.42 | 48.92 | 0.5338 | 1.67 | 5.59 | 394,192.30 | 8.24 | 6.60 | 10.12 | 7.84 | 63.90 | 63.99 | 15.44 | 13.13 | 0.9689 | -- | 0.4114 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
Intuitive Surgical, Inc. | 7.12bn | 1.80bn | 141.81bn | 13.68k | 79.57 | 10.59 | 62.42 | 19.91 | 5.03 | 5.03 | 19.93 | 37.77 | 0.5014 | 2.27 | 6.88 | 520,919.90 | 12.79 | 12.42 | 14.44 | 13.83 | 66.39 | 67.60 | 25.51 | 26.31 | 4.02 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 119.61m | 8.15% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 119.28m | 8.13% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 67.86m | 4.63% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 62.33m | 4.25% |
Massachusetts Financial Services Co.as of 31 Dec 2023 | 57.18m | 3.90% |
PRIMECAP Management Co.as of 31 Dec 2023 | 37.91m | 2.58% |
Wellington Management Co. LLPas of 31 Dec 2023 | 36.44m | 2.48% |
Geode Capital Management LLCas of 31 Dec 2023 | 27.56m | 1.88% |
BlackRock Investment Management (UK) Ltd.as of 31 Dec 2023 | 22.74m | 1.55% |
The Bollard Group LLCas of 31 Dec 2023 | 22.39m | 1.53% |